Advances in Urothelial Cancer Volume II
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2654
Special Issue Editors
Interests: urology; bladder cancer; urologic oncology; hematology; oncology; nephrology
Special Issues, Collections and Topics in MDPI journals
Interests: bladder cancer; drug development; animal model; urine exosome
Special Issues, Collections and Topics in MDPI journals
Interests: urothelial cancer; urologic oncology; medical oncology; drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent advances in genomics technologies have classified molecular subtypes of bladder cancer based on gene expression profiling and have examined their significance in clinical utility to inform prognosis and/or to predict therapeutic responses.
The use of immune checkpoint inhibitors, particularly with antibodies directed against programmed cell death 1 protein (PD-1) or its ligand (PD-L1), has led to important advances in the treatment of metastatic urothelial cancer and been tested in the early stages of bladder cancer. However, only a small number of patients respond to checkpoint inhibitors. Therefore, attempts are being made to develop biomarkers that could help to identify urothelial cancer patients who are likely to respond to these drugs.
As a type of targeted therapy, therapeutic agents such as enfortumab vedotin, an antibody-drug conjugate designed to treat Nectin-4 expressing cancer, and erdafitinib, a small molecule inhibitor of fibroblast growth factor receptor, have been accepted in clinical studies on metastatic bladder cancer.
Additionally, many combinations of therapies are being tested for urothelial cancer, combining either multiple immunotherapy drugs or immunotherapy drugs with other types of treatment. These advances offer patients better monitoring opportunities, unique treatment options, and greater hope for long-term survival.
In this Special Issue on “Advances in the Urothelial Cancer”, we will include the information and available data regarding molecular classification, diagnosis, immunotherapy, various targeted agents, and antibody-drug conjugates that have recently shown promising results against urothelial cancer.
Dr. Ho Kyung Seo
Prof. Dr. Eu Chang Hwang
Dr. Whi-An Kwon
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biology
- bladder cancer
- urothelial carcinoma
- targeted therapy
- biomarkers
- immunotherapy
- chemotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
